contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


asarina-pharma-ab-publ-releases-annual-report-2022

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Asarina Pharma

(Stockholm, 28 April 2023) Asarina Pharma's 2022 Annual Report contains analysis and insights into its recent positive Phase IIa results for Tourette syndrome, as well as 2022 financial statements...

<div class="abstract">(Stockholm, 28 April 2023) Asarina Pharma's 2022 Annual Report contains analysis and insights into its recent positive Phase IIa results for Tourette syndrome, as well as 2022 financial statements and outlook. Additional content includes investor FAQs with CEO Peter Nordkild and clinical insights from Clinical Neurologist Dr Heidi Biernat (Head of the Tourette Clinic at Bispebjerg University Hospital) on today's Tourette treatment landscape and patients' experience of Sepranolone.</div>The full Annual Report 2022 is available on: <a href="https://asarinapharma.com/investors/financial-reports/">https://asarinapharma.com/investors/financial-reports/</a>Research and Development: This year, Asarina's Annual Report includes extra content for shareholders and investors on the company's Phase IIa results for Tourette syndrome. This includes:<ul><li>An extended CEO Statement covering scientific validation, four key takeaways and the company's current activities around Business Development and a future Phase IIb study.</li><li>An Investor FAQ with Asarina's CEO which looks at the competitive landscape for Tourette plus the implications of the study's consistently positive secondary clinical endpoint results.</li><li>Clinical insights from Clinical Neurologist Dr Heidi Biernat on today's treatments for Tourette including antipsychotics and CBIT, plus her observations of Sepranolone in- clinic.</li></ul>Financial results and outlook: throughout 2022, Asarina continued its strict cost-management approach, ensuring cash for the completion of its Phase IIa study. External R&amp;D costs fell to SEK 7.3 million from SEK 29.9 million in 2021. The Group had a net cash outflow of SEK 8.8 million in 2022 compared with SEK 36.8 million in 2021, due to the reduction in R&amp;D and staff costs. At the end of 2022, the Group had total cash of SEK 13.6 million.The positive results from Asarina's Phase IIa study in Tourette Syndrome, in a condition that has long had an unmet need for a safer, more tolerable 1[st] line pharmaceutical treatment, are creating industry interest. Asarina is presently pursuing dialogues with prospective partners within CNS and neurology in particular while at the same time exploring the possibilities for funding of a Phase IIb study. The company has sufficient funds to continue these activities up to at least the end of 2023.Read the full CEO Statement here: <a href="https://asarinapharma.com/investors/financial-reports/">https://asarinapharma.com/investors/financial-reports/</a>

Tilmeld dig vores nyhedsbrev - ingen konto nødvendig!